Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.1552W HIGH $2.85
Volume
111.07 K
Value Traded
28.89 K
Short % Float
2.36%
+1,905.88%Week
+1,114.82%1 Month
+623.38%3 Month
+478.26%6 Month
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
1.95 M
EPS (TTM)
-0.63
P/E Ratio
-
Ent. Value
1.46 M
Total Shares
9.75 M
Float Shares
8.37 M
Insiders
14.08%
Institutions
6.03%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
NXGL Catalyst Timeline
Dated clinical, regulatory and corporate events for NexGel, Inc Common Stock
Past FDA Catalysts and PDUFA Decisions
How NXGL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
NexGel, Inc is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every NXGL program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Levy Adam R.Director, Officer (Chief Executive Officer) | Sell | -5,000 322,692 held | $0.59 | 06/23/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NXGL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in NXGL for Q2 2026. | ||||
NXGL Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NXGL ranks across every disease it competes in
Competitive Position is a premium feature
See how NXGL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNXGL News
-NXGL
Oct 12, 2026▼ -18.1%today
NEXGEL Announces 1-for-20 Reverse Stock Split Effectiveness
NEXGEL, Inc. announced the effectiveness of a 1-for-20 reverse stock split, which will begin trading on a split-adjusted basis on Nasdaq. This move aims to increase the per-share price to comply with Nasdaq's minimum bid price requirement. The reverse split reduces the number of outstanding shares significantly, but there are no guarantees of regaining compliance.
Read more →-NXGL
Sep 23, 2026NEXGEL Announces Dial-In Details for Investor Update Call
NEXGEL, Inc. has announced details for an investor update call scheduled for September 24, 2026. The call will focus on the company's operational progress and commercialization initiatives. Interested parties can join via a live call or access a replay until October 1, 2026. NEXGEL specializes in patient-centric medical technology and has a diverse product range.
Read more →-NXGL
Sep 16, 2026▼ -11.7%on this news
NEXGEL Announces Date for Investor Update Call
NEXGEL, Inc. has announced that it will host an investor update call on September 24, 2026, at 4:15 p.m. Eastern Time. This call will provide updates on the company's operational progress and commercialization initiatives, following a previous announcement made in August. Details for accessing the call will be shared separately.
Read more →-NXGL
Aug 20, 2026▼ -14.8%on this news
NEXGEL ANNOUNCES LEADERSHIP TRANSITION AND STRATEGIC REVIEW INITIATIVE
NEXGEL, Inc. announced a leadership transition with Brian Kieser appointed as Interim CEO. The company has established a Special Committee for Strategic Review and Value Creation to enhance operational execution and liquidity. The committee will evaluate strategic alternatives and focus on the company's highest-value growth opportunities, particularly in the BioNX divisions.
Read more →-NXGL
Aug 17, 2026▼ -33.5%on this newsshared move
NEXGEL Reports Second Quarter 2026 Financial Results
NEXGEL, Inc. reported its second quarter 2026 financial results, revealing a revenue of $3.69 million and a net loss of $2.87 million. The company is undergoing significant transformation following its acquisition of Celularity, Inc., focusing on integrating operations and expanding into the surgical market. Despite challenges in supply chain and slower-than-expected growth, management remains optimistic about future opportunities, particularly in the hospital channel.
Read more →-NXGL
Jun 4, 2026NEXGEL to Present at Planet MicroCap Conference Las Vegas on June 16th –18th
NEXGEL, Inc. will present at the Planet MicroCap Conference in Las Vegas from June 16-18, 2026. CEO Adam Levy is scheduled to speak on June 17 at 1:30 PM PT. The event will take place at the Bellagio Hotel & Casino, offering a platform for investor meetings and showcasing NEXGEL's innovative products.
Read more →-NXGL
May 6, 2026NEXGEL Appoints Brian Kieser and Kevin Harris from New Strategic Partner, Sequence LifeScience , to Board of Directors
NEXGEL, Inc. has appointed Brian Kieser and Kevin Harris from Sequence LifeScience to its Board of Directors. This move follows Sequence LifeScience's strategic investment of $5.5 million, which helped facilitate the acquisition of Celularity's degenerative disease segment. NEXGEL's CEO stated that the new board members bring valuable industry experience and a robust distribution system that can support the company's growth and innovation initiatives. The partnership is seen as a transformative opportunity for NEXGEL.
Read more →-NXGL
Apr 27, 2026▼ -6%on this news
NEXGEL Appoints Ian Blackman as Chief Financial Officer Financial and M&A Leader Appointed to Integrate Acquisition of Celularity, Scale the Business and Accelerate Growth
NEXGEL, Inc. has appointed Ian Blackman as Chief Financial Officer to facilitate the integration of the acquisition of Celularity, enhancing the company's growth prospects. Blackman brings over 30 years of experience in finance and a strong track record in scaling businesses and handling complex transactions. His expertise is expected to be instrumental in advancing NEXGEL's strategic objectives, particularly in expanding its regenerative technology portfolio and improving financial performance. The leadership changes signal a focused effort to leverage Celularity's assets in the healthcare market.
Read more →-NXGL
Apr 21, 2026▲ +15.9%on this news
New Strategic Partner, Sequence LifeScience , Leads Financing with $5.5 Million to Complete Acquisition of Celularity Degenerative
NEXGEL, Inc. has completed an acquisition of commercial-stage regenerative biomaterials from Celularity, facilitated by a $5.5 million investment from Sequence LifeScience. This acquisition is expected to significantly increase NEXGEL's annual revenue, potentially tripling it to approximately $35 million. Alongside this development, NEXGEL has launched BioNX Surgical, a division focused on advanced biomaterials aimed at regenerative medicine. The partnership with Sequence LifeScience is anticipated to enhance product development and commercialization capabilities.
Read more →-NXGL
Mar 10, 2026▼ -15.8%on this news· ran to -27% by day 1
NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products
NEXGEL has signed a definitive agreement with Celularity Inc. to license and acquire a transformative portfolio of commercial-stage regenerative biomaterial products. This transaction is projected to triple NEXGEL's annual revenue reaching approximately $35 million and to make the company immediately profitable upon closing. The acquired products focus on tendon repair, skin grafts, and bone growth, supported by existing insurance reimbursement pathways. The deal will also bring an experienced commercial team to NEXGEL, significantly enhancing its operational capabilities in the medical technology sector.
Read more →-NXGL
Feb 10, 2026NEXGEL Announces Financing of $1.797 Million Relating to an Acquisition Targeted to Close in the First Quarter of 2026, Subject to the Completion
NEXGEL, Inc. announced a financing commitment of $1.797 million aimed at a potential acquisition targeted for completion in the first quarter of 2026. This acquisition is contingent upon successful due diligence by both NEXGEL and the investor. The company has a history of successfully closing several acquisitions, indicating a potential for future growth. Additional funding of up to $14.869 million is possible, depending on the due diligence outcome.
Read more →-NXGL
Dec 11, 2025▲ +22.7%on this news
NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx
NEXGEL, Inc. has announced the spin-off of its drug delivery program into a new entity called NexGelRx, which focuses on Rx drug delivery solutions using proprietary hydrogel technology. Shareholders will benefit from a 19.99% non-dilutive equity interest and a 5% global royalty on products developed by NexGelRx. The funding for NexGelRx includes an initial investment from outside investors, allowing NEXGEL to concentrate on its core manufacturing and consumer branding operations. This strategic move aims to explore high-value drug delivery opportunities without incurring additional costs to NEXGEL.
Read more →-NXGL
Nov 11, 2025NEXGEL Reports Third Quarter 2025 Financial Results
NEXGEL, Inc. reported its third quarter 2025 financial results, revealing a net revenue of $2.93 million, which is slightly lower compared to the same quarter last year. The company's gross profit increased to $1.24 million, resulting in a gross profit margin of 42.4%. Although the net loss attributable to stockholders decreased, the adjusted EBITDA loss remained the same as the previous year. Management highlighted growth in the contract manufacturing sector and new product launches as key drivers for future success.
Read more →-NXGL
Aug 12, 2025NEXGEL Reports Second Quarter 2025 Financial Results
NEXGEL, Inc. reported its second quarter 2025 financial results, showcasing a substantial revenue increase of 100.3% from the previous year, totaling $2.88 million. The company's gross profit margin also improved significantly to 43.6%. Despite this growth, NEXGEL recorded a net loss of $0.67 million. The company reiterated its revenue guidance for the year at $13 million and expressed confidence in achieving positive EBITDA, bolstered by a recent $1 million advance from STADA to support product launches and marketing efforts.
Read more →-NXGL
Aug 5, 2025▲ +5%on this news
NEXGEL Appoints Chief Accounting Officer of Shutterstock, Steve Ciardiello, CPA, to its Board of Directors
NEXGEL, a company specializing in high-water-content hydrogels, appointed Steve Ciardiello, CPA, as a new member of its Board of Directors. Ciardiello currently serves as the Chief Accounting Officer of Shutterstock and brings over 25 years of financial leadership experience. His extensive background in corporate governance and public company operations is anticipated to greatly assist NEXGEL in its growth strategy. The appointment is seen as a significant step forward for the company as it aims to enhance its impact in the healthcare sector.
Read more →-NXGL
Aug 1, 2025▲ +14.2%on this newsshared move
NEXGEL Announces $950,000 Registered Direct Offering and Concurrent Private Placement
NEXGEL, Inc. announced a $950,000 registered direct offering and a concurrent private placement, involving the sale of 413,044 shares at $2.30 each. The company will also issue unregistered warrants for purchase of 206,522 shares at an exercise price of $4.25. The CEO emphasized that the financing, along with a recent $1 million non-dilutive advance, significantly bolsters the company's financial position in anticipation of high growth in the latter half of the year. These transactions are part of NEXGEL's strategy to enhance its working capital as it navigates a critical period.
Read more →-NXGL
Jul 14, 2025▼ -5.2%on this news
NEXGEL and STADA AG Announce Expansion of Partnership for North America
NEXGEL, Inc. has announced an expansion of its partnership with STADA Arzneimittel AG to launch new digestive enzyme formulas and skincare products targeting scars and stretch marks in North America. As part of the agreement, STADA will provide $1 million in financial support to NEXGEL to assist with product launches and marketing efforts. This collaboration demonstrates both companies' commitment to leveraging their strengths for innovative consumer health solutions across the region.
Read more →-NXGL
May 13, 2025NEXGEL Reports First Quarter 2025 Financial Results
NEXGEL, Inc. (NASDAQ: NXGL) announced its financial results for the first quarter of 2025, reporting a revenue increase of 121% to $2.81 million compared to the same period in 2024. The company's gross profit margin also improved significantly to 42.4%, a notable increase from the prior year. Despite these positive financial highlights, NEXGEL still experienced a net loss of $0.71 million but noted a tightening of its EBITDA losses. The CEO expressed confidence in the company's ability to meet its revenue guidance of $13 million for 2025 and achieve positive EBITDA.
Read more →-NXGL
Mar 24, 2025▲ +14.4%on this news
NEXGEL Reports Record Fourth Quarter and Full Year 2024 Financial Results
NEXGEL, Inc. reported record financial results for the fourth quarter and full year 2024. The company achieved significant revenue growth, with fourth quarter revenue reaching $3.04 million, and full year revenue totaling $8.69 million, increases of 181% and 112% year-over-year, respectively. Despite these gains, NEXGEL incurred a net loss of $3.28 million for the year, slightly higher than the previous year's loss. Looking ahead, the company anticipates at least $13 million in revenue for 2025 and expects to achieve positive EBITDA.
Read more →-NXGL
Jan 22, 2025Issues Letter to Shareholders and Provides Guidance for 2024 and 2025
NEXGEL, Inc. has issued a letter to shareholders outlining positive revenue guidance for 2024 and 2025. The company expects Q4 2024 revenues to reach approximately $3.0 million, totaling around $8.6 million for the year, marking over 100% growth year-over-year. Looking into 2025, NEXGEL anticipates generating at least $13 million in revenue and achieving positive cash flow from operations. Additionally, the company highlights several growth areas, including contract manufacturing and new product launches, while acknowledging that current financial estimates are preliminary.
Read more →About NexGel, Inc Common Stock
Headquarters2150 CABOT BLVD WEST,, LANGHORNE, PA, 19047
BIOPHARMAWATCH ELITE PLUS
Trade the next NXGL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime